Trial Profile
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2012
Price :
$35
*
At a glance
- Drugs IDP 107 (Primary)
- Indications Acne vulgaris
- Focus Therapeutic Use
- 06 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Feb 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
- 03 Nov 2011 Planned End Date changed from 1 Jun 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.